

## Myrbetriq® (mirabegron) - First-time generic launch halted

- On April 23, 2024, the Federal Circuit court issued a temporary injunction halting Lupin and Zydus launch of AB-rated generic versions of Astellas' <u>Myrbetriq (mirabegron)</u> 25 mg extended-release tablets.
- Myrbetrig is approved for the following:
  - Treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency
  - In combination with <u>solifenacin succinate</u>, for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency
  - Treatment of neurogenic detrusor overactivity in pediatric patients aged 3 years and older and weighing 35 kg or more.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.